ホーム › びまん性大細胞型B細胞リンパ腫 › オレゴン › Portland
Portland、ORにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
Portlandとその周辺地域（約30マイル以内）の拠点で、びまん性大細胞型B細胞リンパ腫に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
被験者募集中第2相
- Oregon Health and Science University, Portland
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
被験者募集中第3相
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
被験者募集中第2相
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
被験者募集中観察研究
- OHSU Knight Cancer Institute, Portland
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- Oregon Health & Science University (OHSU), Portland
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
被験者募集中第1/2相
- Oregon Health and Science University ( Site 1004), Portland
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- Oregon Health & Science University, Portland
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
被験者募集中観察研究
- Oregon Health and Science University Knight Cancer Institute, Portland
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Oregon Health and Science University Knight Cancer Institute, Portland
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
被験者募集中第1/2相
- OHSU Knight Cancer Institute, Portland
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- 他1件
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12マイル先
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
被験者募集中第1相
- Oregon Health & Science University, Portland
他の都市におけるびまん性大細胞型B細胞リンパ腫の試験
- New York City, NY21件の研究
- Baldwin Park, CA19件の研究
- Chicago, IL18件の研究
- Houston, TX17件の研究
- Los Angeles, CA17件の研究
- Boston, MA16件の研究
- Milwaukee, WI16件の研究
- Nashville, TN15件の研究
- Philadelphia, PA15件の研究
- Durham, NC14件の研究
- Dallas, TX13件の研究
- Seattle, WA12件の研究
Portlandにおける他の研究
- 非小細胞肺癌46件の研究
- がん（全種類）34件の研究
- 前立腺がん33件の研究
- 乳がん33件の研究
- 転移性癌29件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 肺がん26件の研究
- 急性骨髄性白血病25件の研究
- 子宮内膜がん24件の研究
- 頭頸部扁平上皮癌19件の研究
- 膵臓がん19件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。